Amerise Biosciences Limited announced key leadership changes and approved quarterly financial results during its board meeting held on February 2, 2026. The meeting, which commenced at 03:45 PM and concluded at 04:15 PM at the company's registered office, addressed several important corporate matters.

Leadership Transition

The board approved the appointment of Mr. Albert Hines as Whole-time Director and Chief Financial Officer effective February 2, 2026. Simultaneously, the company accepted the resignation of Mr. Dinesh Rathod from the same positions on the same date.

New CFO Profile

Mr. Albert Hines brings relevant experience to his new role at Amerise Biosciences Limited. The 25-year-old executive has more than 3 years of experience in accounts and finance. According to the company's disclosure, Mr. Hines does not hold any shares in the company at the time of his appointment.

Resignation Details

Mr. Dinesh Rathod submitted his resignation citing personal commitments and pre-occupation with other work as the primary reasons for his departure. In his resignation letter dated February 2, 2026, Rathod expressed gratitude to the board members for their cooperation and assistance during his tenure as director.

Financial Results Approval

The board considered and approved the company's unaudited financial results for the quarter and nine months ended December 31, 2025. This approval was made in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The announcements were made pursuant to Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company, formerly known as Amradeep Industries Limited, trades on BSE with scrip code 531681 under the security ID AMERISE.

Amerise Biosciences Limited, a biosciences company based in Ahmedabad, has reported a net loss for the first quarter of the fiscal year 2026, as revealed in its latest financial results.

Financial Performance

The company reported a net loss of Rs. 0.81 lacs for the quarter ended June 30, 2025, a significant shift from the profit of Rs. 10.59 lacs recorded in the previous quarter. This downturn in financial performance was accompanied by a substantial decline in total income, which fell to Rs. 6.37 lacs from Rs. 18.80 lacs in the preceding quarter.

Revenue Breakdown

Interestingly, Amerise Biosciences' revenue for the quarter came entirely from other operating revenue, with no gross revenue reported from product sales. This suggests a potential shift in the company's revenue streams or operational focus.

Expenses

Total expenses for the quarter stood at Rs. 7.18 lacs, primarily consisting of:

• Employee benefit expenses: Rs. 2.32 lacs
• Other expenses: Rs. 4.86 lacs

Key Financial Metrics

The company's paid-up equity share capital remained constant at Rs. 660.69 lacs.

Board Meeting and Auditor's Review

As per the LODR data, the Board of Directors of Amerise Biosciences Limited met on July 24, 2025, to consider and approve the unaudited financial results for the quarter ended June 30, 2025. The meeting commenced at 03:50 PM and concluded at 04:15 PM.

The financial results have been reviewed by the Audit Committee and approved by the Board of Directors. Additionally, the statutory auditors, BIPIN & CO. Chartered Accountants, have carried out a limited review of the financial results, as required by SEBI regulations.

Outlook

While the company has faced a challenging quarter with decreased revenue and a shift to a net loss position, it's important to note that quarterly results can be subject to various factors and may not necessarily indicate long-term trends. Investors and stakeholders will likely be watching closely to see how Amerise Biosciences navigates these challenges in the coming quarters.

Note: All financial figures are in Indian Rupees (Rs.) and are reported in lacs.